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Aims Myocardial fibrosis as detected by late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) is a
powerful prognostic marker in hypertrophic cardiomyopathy (HCM) and may be progressive. The precise mecha-
nisms underlying fibrosis progression are unclear. We sought to assess the extent of LGE progression in HCM and
explore potential causal mechanisms and clinical implications.
...................................................................................................................................................................................................
Methods
and results
Seventy-two HCM patients had two CMR (CMR1-CMR2) at an interval of 5.7 ± 2.8 years with annual clinical
follow-up for 6.3 ± 3.6 years from CMR1. A combined endpoint of heart failure progression, cardiac hospitalization,
and new onset ventricular tachycardia was assessed. Cine and LGE imaging were performed to assess left ventricu-
lar (LV) mass, function, and fibrosis on serial CMR. Stress perfusion imaging and cardiac energetics were under-
taken in 38 patients on baseline CMR (CMR1). LGE mass increased from median 4.98 g [interquartile range (IQR)
0.97–13.48 g] to 6.30 g (IQR 1.38–17.51 g) from CMR1 to CMR2. Substantial LGE progression (DLGE >_ 4.75 g)
occurred in 26% of patients. LGE increment was significantly higher in those with impaired myocardial perfusion re-
serve (<MPRI 1.40) and energetics (phosphocreatine/adenosine triphosphate <1.44) on baseline CMR (P<_ 0.01 for
both). Substantial LGE progression was associated with LV thinning, increased cavity size and reduced systolic func-
tion, and conferred a five-fold increased risk of subsequent clinical events (hazard ratio 5.04, 95% confidence inter-
val 1.85–13.79; P= 0.002).
...................................................................................................................................................................................................
Conclusion Myocardial fibrosis is progressive in some HCM patients. Impaired energetics and perfusion abnormalities are pos-
sible mechanistic drivers of the fibrotic process. Fibrosis progression is associated with adverse cardiac remodelling
and predicts an increased risk of subsequent clinical events in HCM.
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..Introduction
Sudden cardiac death (SCD) and advanced heart failure are recog-
nized complications of hypertrophic cardiomyopathy (HCM).1
Myocardial fibrosis is an important substrate for both life-threatening
arrhythmia and adverse cardiac remodelling2 in HCM.
Histopathological studies confirm a high burden of fibrosis in both
young adults3 who suffered a SCD and older patients with end-stage
heart failure and HCM.4
Cardiovascular magnetic resonance (CMR) permits the in vivo as-
sessment of myocardial fibrosis using late gadolinium enhancement
(LGE) imaging.4–6 The presence and extent of LGE are emerging pre-
dictors of cardiovascular morbidity and mortality in HCM and not
limited to adults.7,8 Recently, a significant proportion of children and
adolescents with HCM were found to have LGE with evidence of
progression on serial imaging.9 Longitudinal studies examining the
rate of LGE progression at longer intervals are sparse9–11 with a lack
of studies examining the clinical relevance of fibrosis progression.
Mechanisms driving fibrosis progression in HCM are also incomplete-
ly understood.9
The myocardium in HCM exhibits characteristic abnormalities in
substrate metabolism and vascular remodelling.12–14 For example,
reduced phosphocreatine to adenosine triphosphate concentration
ratio (PCr/ATP) on phosphorus magnetic resonance spectroscopy
(31P-MRS) is a marker of abnormal energy utilization in HCM and
may play a critical role in its pathophysiology.13,15 Similarly, micro-
vascular dysfunction may trigger fibrosis in HCM, promoting con-
tractile dysfunction.4,14 Dissecting the pathophysiological factors that
cause fibrosis, rather than merely associate, remains a challenge.
Here, we sought to characterize the natural history of myocardial
fibrosis in HCM and explore potential underlying mechanisms.
We assessed whether the extent of LGE progression can serve as a
predictor of clinical events to guide future management.
Methods
Population
This is a retrospective analysis of data from an observational study
approved by local ethics committee (reference: 07/Q1607/66, 12/LO/
1979). All patients with HCM enrolled in this study were recruited from
the University of Oxford Inherited Cardiac Conditions Clinic and all
were invited to have a repeat CMR as a part of the study. Genetic screen-
ing was undertaken for 13 HCM genes and mitochondrial mutations (see
Supplementary data online). Diagnosis of HCM was based on the pres-
ence of unexplained left ventricular hypertrophy (LVH) (maximum left
ventricular wall thickness, LVWT >_ 15 mm) or the presence of a patho-
genic HCM-causing sarcomeric mutation (genotype positive phenotype
negative, GþP- patients included).
Patients with known coronary artery disease, aortic stenosis, amyloid-
osis, or contraindications to CMR were excluded. A total of 88 patients
were included in the study. Of them, 16 were excluded after CMR1. Ten
had ICD’s implanted, two had pacemakers, two had reveal devices
implanted, one had LGE in a myocardial infarction pattern and one had
significant coronary disease on coronary angiography leaving 72 patients
with two CMR scans (CMR1-CMR2) (Figure 1).
CMR protocol
All 72 patients had serial CMR including cine and LGE assessment at 1.5T
or 3T (see Supplementary data online) at an interval of 5.7 ± 2.8 years
(Figure 1). Sixteen patients had follow-up CMR at different field strengths.
Thirty-eight patients also had first pass perfusion imaging and myocardial
energetics assessment at baseline (CMR1) (Figure 1), all 38 had serial
CMR at the same field strength (3T). Cine was undertaken using a series
Figure 1 A flowchart of hypertrophic cardiomyopathy (HCM) patients through the study. CMR, cardiovascular magnetic resonance imaging; ICD,
implantable cardioverter defibrillator; LGE, late gadolinium imaging; 31P, Phosphorus-31 spectroscopy; T, Tesla. *CMR2 was at 1.5T or 3T (see
Supplementary data online).
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..of single breath-hold balanced steady-state free precession images for es-
timation of cardiac volumes and function as previously described.16
LGE imaging was acquired in multiple short-axis slices to match cine
views and long-axis planes approximately 8–10 min after intravenous ad-
ministration of the gadolinium-based contrast agent (GBCA) (total dose
0.15 mmol/kg) for all scans (see Supplementary data online). The inver-
sion time was adjusted for optimal nulling of remote normal myocar-
dium.17 For all CMR scans before 2012, Gadodiamide (Omniscan,
Nycomed Amersham, UK) was used as contrast agent. Due to the
emerging safety concerns of Gadodiamide (Omniscan), in particular the
associated risk of nephrogenic systemic fibrosis, Gadobuterol (GadovistVR ,
Bayer Inc., Toronto, ON, Canada) was used as contrast agent at 1.5T and
Gadoterate meglumine (Dotarem, Guerbet LLC, France) at 3T for all
scans from 2012.18–20
Perfusion imaging was undertaken (before LGE imaging) at 3T on
CMR1 for 38 patients using a T1-weighted gradient echo sequence with
saturation recovery magnetization preparation. Adenosine was used as
pharmacological stress at a rate of 140mg/kg/min and up-titrated by
haemodynamic response. Three short-axis slices (base, mid, and apex)
were acquired. 0.03 mmol/kg of GBCA was injected at 6 mL/s during
stress followed by a saline flush 12 mL at 6 mL/s and the same dose for
rest acquisition. Three patients were excluded [failure of contrast injec-
tion (n= 2) or intolerance to adenosine (n= 1)]. The remaining patients
were adequately stressed as evidenced by the presence of appropriate
haemodynamic response and splenic switch off.16
31P MRS was performed on baseline CMR (3T) to measure myocardial
energetics for 38 patients. Subjects were placed prone with their hearts
over the centre of the coil as previously described.16 The PCr/ATP ratio
from a mid-ventricular septal voxel in a position matching mid ventricular
perfusion slice was obtained (see Supplementary data online).
CMR image analysis
Commercially available software (Circle Cardiovascular Imaging Inc.,
Calgary, Canada) was used to analyse left ventricular (LV) volumes, mass,
ejection fraction, peak systolic 2D global longitudinal, circumferential and
radial strain as previously reported.21 The assessment of LV indices and
LGE mass were undertaken by two observers blinded to the clinical infor-
mation (M.S. and S.S.). Quantitative analysis of LGE was undertaken by
setting a signal intensity threshold at five standard deviations (5 SD) above
the mean intensity of a reference region of interest placed in a remote
area of myocardium with no visual evidence of enhancement.6,22 A binary
visual score (1 = progression; 0 = no progression) was also provided by
an experienced (>5 years) CMR clinician (M.M.) to assess level of agree-
ment between semiquantitative assessment and observed changes seen
by an expert clinician (see Supplementary data online).
For perfusion analysis, signal intensity curves were generated to meas-
ure myocardial perfusion reserve index (MPRI) as previously described.17
Post-processing of 31P-MRS data was performed using the OXSA tool-
box (see Supplementary data online).
Clinical follow-up
Clinical follow-up was performed annually for a period of 6.3 ± 3.6 years
from CMR1. In cases of a suspected event, all medical records were
obtained and reviewed by two observers (B.R. and M.M.) blinded to the
CMR data.
Major risk factors for SCD included traditional risk factors (see
Supplementary data online). Additionally, the European Society of
Cardiology (ESC) risk calculator was used to estimate 5-year SCD risk
for all patients.23
Given the low event rate in this selected population undergoing serial
CMR, we used a composite clinical endpoint of: heart failure progression
defined as a progressive increase in New York Heart Association
(NYHA) class necessitating optimisation of medical therapy, new onset
non-sustained ventricular tachycardia (>_3 heart beats, >_120 bpm), and
hospitalization from cardiac cause (arrhythmia or heart failure). A change
in NYHA class or medical therapy due to intolerance to medications did
not constitute a clinical event in this study.
Statistical analysis
Statistical analyses were undertaken using IBM SPSS Statistics 23.0 (IBM
Corp., Armonk, NY, USA), STATA/SE 15.0 (Stata Corp, College Station,
TX, USA), and GraphPad Prism 7.0 (GraphPad Software, San Diego, CA,
USA). Normality of data was assessed by visually inspecting the plots.
Mean (with standard deviation, SD) and median (with interquartile range,
IQR or confidence intervals, CI for median differences) were computed
as appropriate. Paired t-test and Mann–Whitney tests were used for nor-
mally distributed and non-Gaussian data respectively. The v2 and Fisher’s
exact tests were used to compare proportions. Given the current lack of
a generally accepted cut off for ‘significant’ LGE progression (DLGE), a re-
ceiver operator curve was used to estimate the optimal DLGE threshold
(Youden index) predictive of clinical events, which was an increment of
4.75 g (see Supplementary data online, Figure S1). Univariate and multi-
variable binary logistic regression were used to assess predictors of
DLGE >_ 4.75 g (binary variable).24 LGE mass at CMR1 was treated as a
continuous variable. Kaplan–Meier curves were computed to visualize
the cumulative patients event rates. A multivariable Cox proportional
hazard model was used to analyse independent associations with clinical
outcomes. The covariates included were variables known to be potential
confounders and were adjusted for in the model. All tests were two-
tailed and P-values <0.05 (after Bonferroni correction) were considered
significant.
Results
Study population
The final population consisted of 72 patients with paired CMR data.
Table 1 lists their background characteristics at baseline CMR
(CMR1) and second CMR (CMR2).
Mean age of patients at CMR1 was 45± 12 years and 68% were
male. At CMR1, the majority (94%) had one or no SCD risk factors,
and four (6%) had two or more SCD risk factors (Table 1). The mean
5 year estimated risk of SCD on ESC risk calculator was low at
2.01 ± 0.86%.
By CMR2, patients were more likely to receive aspirin. The ESC
5-year estimated risk of SCD was also slightly higher (2.31 ± 1.44%,
P= 0.01) at CMR2 (Table 1). Other baseline characteristics did not
vary significantly.
Influence of field strengths and contrast
agents on LGE progression
In this observational study, 16/72 patients had follow-up CMR at dif-
ferent field strengths. Despite this, there was no association between
changing field strength and fibrosis progression (b = -0.08, P= 0.64).
We further assessed if the use of a specific combination of GBCA
was associated with LGE progression. On univariate analysis, there
Progression of myocardial fibrosis in hypertrophic cardiomyopathy 159
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
was no association between the varying GBCA combinations and
LGE progression (b -0.73, P= 0.10).
Left ventricular volumes, function, mass,
and LGE from CMR1 to CMR2
The mean LV end-diastolic volume (LVEDV), LV ejection fraction
(LVEF), and mass at CMR1 were 152 ± 30 mL, 67 ± 6%, and
146 ± 52 g respectively. LVEDV and LVEF did not differ between
CMR1 and CMR2 (Table 1). In contrast, a significant increase in LV
mass between scans was detected (146± 52 g vs. 151 ± 52 g,
P= 0.02) (Table 1). Modest reductions in both peak LV global circum-
ferential (GCS) and longitudinal (GLS) strain were also seen from
CMR1 to CMR2 (GCS -18 ± 3% vs. -17 ± 4%, GLS -17± 3% vs.
-16 ± 3%; P< 0.05 for both).
LGE was present in 75% of HCM patients at CMR1, increasing to
82% at CMR2 (Table 1). LGE mass progressed from a median 4.98 g
(IQR 0.97–13.48 g) on CMR1 to 6.30 g (IQR 1.38–17.51 g) on CMR2
(Figure 2A). As a relative proportion of LV mass, the median incre-
ment was 0.74% (95% CI 0.25–1.27%, P< 0.0001) from CMR1 to
CMR2 (Figure 2B). LGE increment >_4.75 g was seen in 26% (n= 19)
of patients.
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of patients with HCM at CMR1 and CMR2
CMR 1 (n572) CMR 2 (n5 72) P-value
Age (years) 45 ± 12 51 ± 12 <0.001
Male, % (n) 68 (49) 68 (49) 1.00
Body mass index (kg/m2) 27 ± 5 27 ± 5 0.08
Hypertension, % (n) 10 (7) 11 (8) 1.00
Diabetes, % (n) 3 (2) 6 (4) 0.68
Smoker, % (n) 7 (5) 6 (4) 1.00
Atrial fibrillation, % (n) 7 (5) 10 (7) 0.76
SCD risk
Family history of SCD, % (n) 26 (19) 26 (19) 1.00
Unexplained syncope, % (n) 4 (3) 4 (3) 1.00
NSVT on Holter monitor, % (n) 10 (7) 24 (17) 0.04
Abnormal exercise BP response, % (n) 1 (1) 3 (2) 1.00
Maximum LV wall thickness >_30 mm, % (n) 4 (3) 4 (3) 1.00
LV outflow tract gradient, % (n) 15 (11) 15 (11) 1.00
NYHA Class I, II, III, IV, % (n) 82, 14, 4, 0 (59, 10, 3, 0) 67, 25, 8, 0 (48, 18, 6, 0) 0.11
ESC risk score 2.01 ± 0.86 2.31 ± 1.44 0.01
SCD risk factors (0/1/2/3 risk factors), % (n) 61, 33, 6, 0 (44, 24, 4, 0) 47, 46, 6, 1 (34, 33, 4, 1) 0.29
Medications
b-Blockers, % (n) 50 (36) 65 (47) 0.06
Calcium channel blockers, % (n) 8 (6) 17 (12) 0.27
Disopyramide, % (n) 6 (4) 15 (11) 0.09
ACEI/ARB, % (n) 14 (10) 14 (10) 1.00
Diuretics, % (n) 6 (4) 7 (5) 1.00
Aspirin, % (n) 25 (18) 47 (34) 0.006
Warfarin, % (n) 6 (4) 11 (8) 0.36
CMR findings
LVEF (%) 67 ± 6 67 ± 7 0.44
LVEDV (mL) 152 ± 30 155 ± 32 0.12
LVEDV index (mL/m2) 79 ± 14 79 ± 14 0.43
LVESV (mL) 51 ± 15 51 ± 18 0.67
LA diameter (in LVOT/three-chamber view) 37 ± 6 37 ± 7 0.37
Stroke volume (mL) 101 ± 19 104 ± 20 0.11
LV mass (g) 146 ± 52 151 ± 52 0.02
LV mass index (g/m2) 75 ± 25 76 ± 27 0.15
Max LVWT(mm) 19 ± 6 19 ± 5 0.79
Presence of LGE, % (n) 75 (54) 82 (59) 0.31
Data are represented as mean ± standard deviation.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; EDV, end-diastolic volume; EF, ejection fraction; ESC, European Society
of Cardiology; ESV, end-systolic volume; HCM, hypertrophic cardiomyopathy; LA, left atrial; LGE, late gadolinium enhancement (5-SD); LV, Left ventricular; LVOT, left ventricu-
lar outflow tract; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death; WT, wall thickness.
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at CMR1 were significant predictors of DLGE >_ 4.75 g (Table 2). On
multivariable analysis, LGE mass at CMR1 remained the only predict-
or ofDLGE >_ 4.75 g (Table 2).
Relationship between LV wall thickness
and LGE progression
Maximum end-diastolic LVWT did not differ significantly between
the two CMR scans (19 ± 6 mm vs. 19 ± 5 mm, P= 0.79) (Table 1).
Thirty-two (45%) had stable LVWT on follow-up, 24 (33%) had a
modest increase (3.0 ± 1.6 mm) in LVWT, and 16 (22%) patients had
a reduction of LVWT. Seven (10%) had a reduction of >3 mm.
Interestingly, patients with regression of wall thickness (WT-) had a
significantly higher extent of LGE increment (Figure 3A–C) vs. those
with stable or increasing LVWT (WT0/þ)- median LGE difference of
6.92 g (95% CI 2.72–10.40 g, P< 0.0001) between groups (Figure 3C).
Two individuals with LVWT regression may have been reclassified to
a lower risk group based on the assessment of traditional major SCD
risk factors at CMR2 alone. Maximum LVWT at CMR1 correlated
Figure 2 Comparison of (A) LGE mass and (B) relative LGE mass from CMR1 to CMR2 (***P< 0.0001, error bars represent SD). (C) a representa-
tive case of fibrosis progression in HCM (blue arrows indicate new regions of fibrosis).
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. moderately with LGE progression (r= 0.36, P< 0.002). At CMR2, a
weaker association was seen between LVWT and LGE progression
(r= 0.28, P= 0.03). With regards to morphological variants, there
were no differences in LGE increment between apical (n= 6) and
non-apical HCM.
Impact of substantial LGE progression on
LV volumes and function
In the subgroup of patients with DLGE >_ 4.75 g (n= 19), there was a
significant increase in LVEDV from CMR1 to CMR2 (CMR1
161± 30 mL vs. CMR2 169± 37 mL, P= 0.04) (Figure 3A and B) with
reduction in LVEF (CMR1 65± 7% vs. CMR2 62 ± 7%, P= 0.03) and
GLS (-16 ± 3% vs. -15 ± 3%, P= 0.04) (Figure 3D and E). There was no
difference in LV mass seen despite these changes.
Relationship between genotype and LGE
progression
Forty-five (63%) patients had sarcomeric mutations; three (4%) had
mitochondrial mutation; three (4%) had a variant of uncertain signifi-
cance in a sarcomeric gene; no pathogenic mutation was found in 21
(29%) patients (see Supplementary data online, Table S1). Nine
patients were pre-hypertrophic (max LVWT <_ 13 mm) sarcomeric
.................................................................................................
Table 2 Univariate and multivariable predictors of
LGE progression (DLGE4.75g)
OR 95% CI P-value
Univariate analysis
Age at CMR1 1.01 0.97–1.06 0.70
Max LV wall thickness at CMR1 1.25 1.10–1.42 0.001
LV mass at CMR1 1.01 1.01–1.03 0.005
LGE mass at CMR1 1.13 1.06–1.21 <0.001
LVEF at CMR1 0.94 0.86–1.02 0.13
Interval between CMR1-CMR2 (days) 1 1.00–1.01 0.50
Genotypea 1.93 0.55–6.73 0.30
Apical vs. non-apical hypertrophy 1.44 0.24–8.59 0.68
Baseline SCD risk (0 or >_1) 0.47 0.15–1.48 0.19
Multivariable analysis
Age at CMR1 1.01 0.95–1.07 0.76
Max LVWT at CMR1 1.14 0.96–1.34 0.14
LV mass at CMR1 0.99 0.99–1.01 0.94
LGE mass at CMR1 1.10 1.02–1.19 0.02
CI, confidence interval; CMR, cardiac magnetic resonance imaging; EF, ejection
fraction; LGE, late gadolinium enhancement; LV, left ventricular; LVWT, left ven-
tricular wall thickness; OR, odds ratio; SCD, sudden cardiac death.
aSarcomeric and mitochondrial mutations vs. genotype negative.
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..mutation carriers (GþP-). On univariate analysis, genotype did not
predict significant LGE progression.
None of the nine sarcomeric GþP- patients had progression of
LGE >_ 4.75 g over a CMR interval of 6 ± 3 years. However, LGE pro-
gression did occur in those with (GþPþ) sarcomeric HCM (2.79 g
IQR 1.12–7.39 g, P< 0.01) vs. GþP- patients (0.17 g, IQR 0.18–1.03 g)
(see Supplementary data online, Figure S2). In patients with LVH
(LVWT >_ 15 mm), differences in LGE increments could also be seen
between those with and without sarcomeric mutations.
Mitochondrial mutation carriers had the highest median LGE incre-
ment of 23.16 g (IQR 16.84–45.78 g) (P< 0.01 for all comparisons)
followed by sarcomeric mutation 2.79 g (IQR 1.12–7.39 g) and geno-
type negative patients 0.52 g (IQR -0.38 to 2.43, P= 0.01 for compari-
son between genotype negative and sarcomeric mutation) (see
Supplementary data online, Figure S2).
Impaired energetics and myocardial
perfusion reserve are associated with
LGE progression
Myocardial energetics were assessed in 38 patients at CMR1.
DLGE >_ 4.75 g was seen in 14 patients. An impairment in energetics
was defined as less than two standard deviations of previously
reported healthy range (1.71± 0.35).16 In those with impaired ener-
getics (PCr/ATP <1.44), there was a significantly higher LGE incre-
ment on follow-up compared with those with normal energetics
(median increment 7.99 g IQR 5.01–17.41 g vs. 1.20 g IQR -0.05 to
25.39, P= 0.01) (Figure 4A). Additionally, patients with DLGE >_ 4.75 g
had reduced myocardial energetics at baseline compared with those
with less progression (PCr/ATP 1.58 ± 0.34 vs. 1.96 ± 0.41, P= 0.006)
(Figure 4C).
Adenosine first-pass perfusion imaging was performed in 35
patients at CMR1. Inducible perfusion abnormalities were seen in 25
patients and DLGE >_ 4.75 g was seen in 13 patients. LGE progression
commonly involved myocardial segments with inducible perfusion
defects at baseline. Seven subjects developed de novo LGE in regions
without inducible perfusion defects. Based on a previous study, an
MPRI < 1.40 was considered suggestive of microvascular dysfunc-
tion.25,26 Patients with impaired MPRI on baseline CMR had a higher
LGE increment on interval scans compared with normal MPRI (me-
dian 9 g IQR 1.47–17.91 g vs. 0.74 g IQR -0.08 to 2.37 g, P< 0.01)
(Figure 4B). In patients with DLGE >_ 4.75 g, MPRI was severely
impaired on CMR1 compared with those with less progression
(1.18 ± 0.23 vs. 1.74± 0.53, P= 0.001) (Figure 4D).
Figure 4 LGE mass increases from CMR1-CMR2 in HCM patients with (A) impaired myocardial energetics and (B) impaired myocardial perfusion
reserve index at baseline CMR. (C) Myocardial energetics and (D) perfusion reserve index are impaired in those with substantial LGE progression.
(MPRI, myocardial perfusion reserve index; PCr/ATP, phosphocreatine to adenosine triphosphate ratio; **P < 0.01, *P < 0.05, DLGE >_ 4.75 g LGE
progression of >_4.75 g or substantial LGE increment, error bars represent standard deviation).
Progression of myocardial fibrosis in hypertrophic cardiomyopathy 163
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Progression of fibrosis predicts clinical
outcomes
In the final cohort of 72 patients, eight underwent primary prevention
ICD implantation subsequent to CMR2. There were no deaths,
aborted cardiac deaths or appropriate ICD shocks. Twenty-four had
clinical events as previously defined. New onset ventricular tachycar-
dia was detected in 13 patients. All cases of new onset NSVT were
detected on 24 hour ECG monitor prior to the implantation of de-
vice. Progression of heart failure with optimization of therapy
occurred in nine patients. Three hospital admissions occurred due to
progression of heart failure symptoms and atrial fibrillation.
Amongst those with any LGE at baseline, 41% developed a clinical
event during the follow-up period (CMR1 to end of study). In con-
trast, 79% of those with DLGE >_ 4.75 g developed a clinical event on
follow-up. In a univariate cox regression analysis, maximum LVWT
on CMR1, initial LGE mass, DLGE >_ 4.75 g were significant predictors
of clinical outcomes (Table 3). On multivariable analysis,
DLGE >_ 4.75 g remained an independent predictor of outcome des-
pite adjusting for age at outcome, maximum LVWT and LGE mass at
CMR1 [hazard ratio (HR) 5.04, 95% CI 1.85–13.79; P= 0.002]. HCM
patients with DLGE >_ 4.75 g had a significantly lower freedom from
clinical events compared with others (Figure 5A). Similarly, patients
with baseline LGE of >_15% of LV mass had a low freedom from clin-
ical events but to a lesser extent than LGE progression (Figure 5B).
Discussion
Our study demonstrates that myocardial fibrosis, quantified by LGE,
is progressive in a proportion of HCM patients, and clinically relevant
LGE progression is characterised by adverse cardiac remodelling.
We also provide novel insights into potential mechanisms of LGE
progression including the relative contributions of underlying genetic
mutations, impaired myocardial energetics and microvascular dys-
function, biological mechanisms believed to promote myocardial fi-
brosis, and hypertrophy in HCM.4,13,27 Although there were no
deaths in this cohort, significant LGE progression in HCM strongly
associated with the risk of escalating heart failure and arrhythmia
symptomatology over time. These findings suggest that therapies
with energy sparing, vascular protective or anti-fibrotic effects may
be beneficial in preventing progression of heart failure and arrhythmic
risk in HCM.
Progression of myocardial fibrosis in
HCM associates with adverse cardiac
remodelling
LGE on CMR provides a robust and reproducible tool for the assess-
ment of myocardial fibrosis in HCM.4–6 Previous small proof-of-
principle studies examining LGE in HCM report an increase at inter-
vals of 1.5–1.9 years.10,11 However, changes in LV function and
adverse remodelling in HCM are a gradual process in HCM, likely to
be missed on short interval scans.28 We, therefore, examined fibrosis
progression over a longer interval. Consistent with others, we report
a modest but significant increase in both LGE mass and relative LGE
mass (proportion of LV mass). Although we observed a smaller
amount of LGE progression compared with previous work (median
LGE increment 6 g in Ref.10), we believe this likely reflects the lower
baseline risk profile of our patients with the inclusion of GþP-
patients in this cohort.
The extent of LGE at a single time point has previously shown to
associate with LV dysfunction and incidence of heart failure.8
Interestingly, a recent study by Todiere et al.10 reported an increased
burden of heart failure symptoms in those with higher LGE progres-
sion rate. Here, we show that HCM patients with clinically relevant
LGE progression have evidence of adverse ventricular remodelling,
including increased LV cavity size, reduced ejection fraction, and glo-
bal longitudinal strain. These findings are unique to this study and pos-
sibly reflect the longer intervals between scans in this study. This may
also explain the increased event rate in those with substantial LGE
progression.
Maximum LVWT can regress due to LGE
progression
We did not see a significant increase in maximum wall thickness from
CMR1 to CMR2. Instead, maximum thickness at CMR1 strongly asso-
ciated with LGE progression suggesting that those with pre-existing
hypertrophy tend to develop LGE progression. Importantly, we
observed that while in some patients maximum wall thickness
increased over time, others had regression associated with a signifi-
cant rise in LGE burden. Indeed, previous studies have reported a link
between LGE mass at a single time point and myocardial thinning on
follow-up echocardiography.29,30 However, no study to date has sys-
tematically assessed the contribution of LGE progression to myocar-
dial wall thinning. Importantly, in two of our subjects, this
phenomenon lead to a reclassification of SCD risk to lower risk based
on traditional risk factors at CMR2. Therefore, our data suggests that
.................................................................................................
Table 3 Univariate and multivariable Cox regression
analysis of predictors of clinical outcomes in HCM
HR 95% CI P-value
Univariate Cox
Age at outcome 0.98 0.95–1.01 0.36
Gender 0.83 0.36–1.91 0.66
Maximum LVWT at CMR1 1.10 1.03–1.17 0.007
LV mass at CMR1 1.01 0.99–1.01 0.12
LGE mass at CMR1 1.04 1.01–1.07 0.002
LGE Progression >_4.75 g 5.53 2.39–12.78 <0.001
Interval between CMR1-CMR2 (days) 1.00 0.99–1.00 0.39
LVEF CMR1 1.01 0.94–1.08 0.85
Apical vs. non-apical hypertrophy 2.21 0.63–7.33 0.22
Genotypea 1.94 0.66–5.69 0.23
Baseline SCD risk factors 0.51 0.21–1.25 0.14
Multivariable Cox
Age at outcome 0.98 0.94–1.01 0.19
Maximum LVWT at CMR1 1.07 0.96–1.19 0.25
LGE mass at CMR1 0.98 0.94–1.03 0.52
LGE Progression >_4.75 g 5.04 1.85–13.79 0.002
CI, confidence interval; CMR, cardiac magnetic resonance imaging; HR, hazard
ratio; LVEF, left ventricular ejection fraction; LVWT, left ventricular wall thick-
ness; SCD, sudden cardiac death.
aSarcomeric and mitochondrial mutations vs. genotype negative.
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.the assessment of maximum wall thickness without information on
LGE burden may potentially underestimate the perceived SCD risk in
individuals with HCM. These observations highlight a complex rela-
tionship between progression of LGE and degree of LV hypertrophy
which may inform clinical protocols for follow-up surveillance.
Genotype may influence LGE
progression in the hypertrophied
ventricle
We assessed the significance of underlying pathogenic mutations and
LGE progression in HCM. Genotype did not associate with LGE pro-
gression, possibly due to the inclusion of GþP- patients in our cohort
who did not develop hypertrophy or significant LGE progression.
These findings are concordant with a previous study by Ho et al.,31
who showed that phenotype negative carriers lacked LGE despite
evidence of increased collagen synthesis, due to a compensatory in-
crease in collagen degradation.31 Interestingly, in those with sarco-
meric mutation and overt hypertrophy, this dynamic equilibrium
between collagen synthesis and degradation was lost resulting in a sig-
nificantly higher LGE. Indeed, when we assessed sarcomeric mutation
carriers with overt hypertrophy, patients had significantly higher LGE
progression compared with those with a pre-hypertrophic pheno-
type (GþP–) (See Supplementary data online, Figure S2). Those with
sarcomeric HCM were also found to have a higher burden of LGE
progression than genotype negative patients. In a cross sectional
study by Olivotto et al.,32 similar observations were made about the
prevalence of LGE in sarcomeric mutation vs. genotype negative
HCM. This suggests that factors arising either directly from the ex-
pression of sarcomeric mutations or due to modifier gene effects33,34
possibly promote both hypertrophy and fibrosis in sarcomeric
HCM.35
Interestingly, patients with a metabolically deficient phenocopy of
HCM—mitochondrial HCM showed the highest increase in LGE
when compared with sarcomeric and genotype negative patients.
Previous studies in transgenic mouse models of sarcomeric mutations
also suggest that increased ATP utilization and altered calcium-
dependent signalling may play a central role in disease progression in
HCM.27 Our data provides further evidence that HCM characterized
by ‘energy costly’ mutations are at greatest risk for fibrosis progres-
sion following the onset of LV hypertrophy. Here, we were unable to
examine differences within genetic subgroups and given the limited
scale of our study, further validation of our findings in a larger geno-
typed HCM cohort will most certainly be required.
Impaired energetics and microvascular
dysfunction underlie LGE progression
in HCM
Impairment in myocardial energetics is important in the development
of heart failure,36 but studies examining its long-term sequelae in
HCM are lacking. Metabolic therapies that improve energetic deficits
have been promising at improving functional capacity in HCM,15
though their role in preventing hypertrophy and fibrosis remains to
be elucidated. Here, we found that HCM patients with impaired
Figure 5 Kaplan–Meier curves depict the freedom from clinical events in HCM patients with LGE increment >_4.75 g or less (A) and in those with
LGE on CMR1 >_ 15% of LV mass or less (B) (error bars represent 95% confidence intervals).
Progression of myocardial fibrosis in hypertrophic cardiomyopathy 165
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..myocardial energetics at baseline have a higher burden of LGE pro-
gression at follow-up and conversely in those with substantial LGE
progression, myocardial energetics were severely impaired. This sug-
gests that impairment in myocardial energetics may contribute to the
risk of fibrosis progression in HCM. Future studies evaluating the
effects of metabolic therapies on LGE burden may provide valuable
insights into the role of impaired energetics in disease progression.
The non-invasive assessment of microvascular dysfunction can
predict adverse cardiac remodelling.4,14 Several cross-sectional stud-
ies report a strong association between microvascular dysfunction
and LGE burden,37,38 but its role in promoting fibrosis is unclear. We
observed that HCM patients with impaired myocardial perfusion re-
serve had more LGE progression. Importantly, in those with substan-
tial LGE progression and adverse remodelling, myocardial perfusion
reserve was severely compromised. It therefore follows that micro-
vascular dysfunction may promote fibrosis progression which in turn
causes adverse cardiac remodelling. The development of de novo
regions of fibrosis suggests that factors other than microvascular dys-
function likely contribute to fibrosis progression in HCM including
energetic impairment, pro-fibrotic signalling and inflammation.13,31,39
Progression of fibrosis predicts
composite clinical endpoints
We assessed if LGE progression could predict clinical events that
could potentially alter clinical management. We found that
DLGE >_ 4.75 g was the strongest predictor of clinical sequelae with
an age-adjusted HR of 5.02 (P= 0.02) on multivariable analysis despite
adjusting for baseline LGE mass. These findings highlight the import-
ance of longitudinal assessment of LGE as a dynamic pathological pro-
cess, given its predictive capacity over and above a single
measurement of LGE. Although LGE was seen in the majority of indi-
viduals at baseline, only 41% of them experienced a clinical event. On
the other hand, 79% of those with LGE progression had a clinical
event highlighting the common discordance between LGE prevalence
and clinical outcome. Our study suggests that assessing the temporal
profile of disease activity (LGE progression) rather than just the pres-
ence of LGE, a ‘fossil’ of disease activity, may help identify those at
risk of clinical deterioration. This is further illustrated by the freedom
from clinical event curves, which demonstrate that LGE progression
was better than LGE extent >_15% at CMR1 for discriminating those
with an evolving disease from others with a stable clinical course.
Study limitations
This is a single-centre study limited by relatively small sample size with
low SCD risk due to the exclusion of those with ICD after CMR1.
Despite our encouraging data, given the lack of hard clinical endpoints
in our cohort, the prognostic value of LGE progression for major car-
diovascular events requires further investigation—in this context, the
recent large international multicentre Hypertrophic Cardiomyopathy
Registry study (HCMR; n= 2764) could provide an ideal platform for
repeat imaging of phenotype progression over time.40
The LGE technique used in this study detects mostly focal fibrosis.
The accuracy of prevalence estimates of LGE progression may also
be limited due to the small sample size. In this study, histological valid-
ation of LGE progression by endomyocardial biopsy was not feasible.
However, previous studies of septal myomectomy and endomyocar-
dial biopsies from HCM patients confirm a strong correlation be-
tween the extent of myocardial fibrosis detected on biopsy and LGE
on CMR.6,41
We acknowledge that the use of different contrast agents at
CMR1 and CMR2 and different field strengths for some patients on
serial CMR assessments are potential limitations of this study, but
there was no evidence that these factors affected the rate of LGE
progression. The predictive value of LGE progression may be lower
than the current estimates from the multivariable analysis due to
over-fitting when applying the method prospectively.
Another limitation of this study is the grouping of patients with sar-
comeric mutations, which may be an oversimplification, and larger
longitudinal studies of LGE imaging in genotyped cohorts will be
needed to assess potential differences among individual sarcomeric
mutations.
Conclusions
This study has demonstrated that clinically significant progression
of myocardial fibrosis occurs in some adults (26%) with HCM over a
6-year period. Impairment of myocardial energetics and perfusion re-
serve may play a pathophysiological role. The detection of fibrosis
progression on CMR advances our ability to identify patients at risk
of developing adverse LV remodelling, heart failure progression and
arrhythmia.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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